Hepatic Cell Reprogramming via Transcription Factor Overexpression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating hepatic cells from induced pluripotent stem cells (iPSCs) are not sufficient for high-throughput drug screens due to metabolic deficiencies and lack of scalability, and existing hepatic cell sources like immortalized cell lines and primary hepatocytes are limited in functionality and consistency.
Innovation Solution
A method involving the overexpression of a combination of at least three transcription factors, including FOXA1 or FOXA3, NR1I2 or NR1I3, HHEX, and others, in non-hepatic cells to induce hepatic cell differentiation, using targeted genetic modifications and culturing techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current state-of-the-art methods are used to generate hepatic cells from iPSCs, then cell production is achieved, but the cells remain metabolically deficient and lack sufficient functionality for high throughput drug screens
Solution Approach 1:
The patent changes the parameters of transcription factor expression by overexpressing a specific combination of transcription factors (FOXA1 or FOXA3, NR1I2 or NR1I3, HHEX, and at least one from additional groups) to transform iPSCs into hepatic cells with improved metabolic functionality and drug-metabolizing capacity suitable for high throughput screening
2Reliability
If primary hepatocytes are used for drug screens, then authentic hepatic function is obtained, but supply is limited and batch-to-batch variation occurs
Solution Approach 1:
The patent creates copies of authentic hepatocyte function by differentiating iPSCs into hepatic cells that replicate the metabolic and drug-metabolizing capabilities of primary hepatocytes, thereby providing a scalable and consistent alternative that maintains functional authenticity
Solution Approach 2:
The patent modifies the transcriptional profile of iPSCs by overexpressing specific transcription factors to change their differentiation state and functional parameters, enabling them to acquire hepatocyte-like metabolic functions while maintaining scalability
3Productivity
If immortalized hepatic cell lines are used for screens, then scalability is improved, but key hepatic drug metabolizing functions are lost
Solution Approach 1:
The patent changes the functional parameters of scalable cell populations by overexpressing transcription factors that restore and enhance drug-metabolizing enzyme expression, thereby maintaining both scalability and authentic hepatic function simultaneously
Data Source
AI summary
The invention relates to methods of generating hepatic cells by overexpressing combinations of transcription factors, in particular for use in cellular reprogramming methods.